Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
出版年份 2022 全文链接
标题
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 23, Issue 2, Pages 220-233
出版商
Elsevier BV
发表日期
2022-01-15
DOI
10.1016/s1470-2045(21)00650-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
- (2021) Jie Wang et al. JAMA Oncology
- Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
- (2021) Shun Lu et al. Journal of Thoracic Oncology
- Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
- (2021) Caicun Zhou et al. Journal of Thoracic Oncology
- PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
- (2021) M. Johnson et al. Journal of Thoracic Oncology
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
- (2020) Robert Jotte et al. Journal of Thoracic Oncology
- Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)
- (2020) Yunpeng Yang et al. Journal of Thoracic Oncology
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial
- (2020) Makoto Nishio et al. Journal of Thoracic Oncology
- Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
- (2020) Caicun Zhou et al. Lancet Respiratory Medicine
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
- (2019) Urania Dafni et al. LUNG CANCER
- Abandoning the Notion of Non-Small Cell Lung Cancer
- (2019) Valeria Relli et al. TRENDS IN MOLECULAR MEDICINE
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
- (2018) Mark A. Socinski et al. Journal of Thoracic Oncology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Microenvironment Differences between Squamous and Non-squamous Non-small Cell Lung Cancer and Their Influence on the Prognosis
- (2018) Xiangjiao Meng et al. Clinical Lung Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating Survival in Patients With Lung Cancer and Brain Metastases
- (2017) Paul W. Sperduto et al. JAMA Oncology
- Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
- (2015) Daniel Morgensztern et al. Journal of Thoracic Oncology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started